Perhaps most intriguingly, treatment of CKD mouse models with an AhR inhibitor effectively rescued the effects of CKD on neovascularization and increased capillary β-catenin and vascular endothelial growth factor expression. Here, VEGFA is linked to chronic kidney disease.